Printed From:

QUESTIONS ABOUT NOVEL CORONAVIRUS?
CLICK HERE.

Consider prescribing DUPIXENT for your patients with inadequately controlled severe asthma

  • DUPIXENT is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with Type 2 inflammation characterised by raised blood eosinophils (EOS) and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with high-dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment1
DUPIXENT is a fully human monoclonal antibody that binds specifically to the IL-4Rα subunit and inhibits IL-4 and IL-13 signalling1

The impact of severe asthma can differ from person to person2

James

Julie

Danielle

JAMES

Clinical profile

  • 60 years old
  • Late onset severe asthma
  • ≥4 annual exacerbations
  • Current treatment: daily high-dose inhaled corticosteroid (ICS) plus long-acting ß2-agonist (LABA)
Blood EOS level Total IgE Baseline FeNO Lung function (FEV1)
200 cells/µL 380 IU/mL 25 ppb 50%

Impact

I am constantly scared about my asthma getting worse

  • Struggles to complete normal everyday tasks and needs constant support from family and friends
  • Lives alone and is afraid that he might have an exacerbation where he cannot dial 999 for help
  • Frequently visits the hospital accident and emergency (A&E) department and has been on a ventilator numerous times

JULIE

Clinical profile

  • 35 years old
  • Severe asthma
  • ≥5 annual exacerbations
  • Current treatment: daily high-dose inhaled corticosteroid (ICS) plus long-acting ß2-agonist (LABA)
Blood EOS level Total IgE Baseline FeNO Lung function (FEV1)
150 cells/µL 35 IU/mL 35 ppb 60%

Impact

I am fed up with taking so many medicines with no improvement

  • Frequent absences from work stopping her from progressing her career
  • Fed up with the amount of medications she has taken for her severe asthma with little or no effect
  • Finds it difficult to care for her three young children and always needs support from partner and other family members with childcare
  • Tired and angry with lack of sleep as woken up numerous times at night

DANIELLE

Clinical profile

  • 12 years old
  • Current treatment: daily high-dose inhaled corticosteroid (ICS) plus long-acting ß2-agonist (LABA)
  • ≥4 annual exacerbations
Blood EOS level Total IgE Baseline FeNO Lung function (FEV1)
300 cells/µL 170 IU/mL 30 ppb 70%

Impact

I don’t want to feel anxious, I just want to live a normal life

  • Always anxious about when asthma will cause a problem leading to no social life as she is restricted to her medication schedule
  • 8 prolonged absences from school over the past year due to asthma symptoms and exacerbations
  • Unhappy with the weight gain associated with taking ICS, leaving her feeling depressed from the lack of control with her weight
  • Exhaustion from night-time awakening

Patients like James, Julie and
Danielle can benefit from
treatment with DUPIXENT

  • DUPIXENT significantly reduces asthma exacerbations, improves lung function and improves quality of life, compared to placebo3–6
  • DUPIXENT has a long-term safety profile observed in clinical studies of adults and adolescents1

INTRODUCING THE DUPIXENT PRE-FILLED PEN

A convenient option to ensure patients
administer DUPIXENT as directed1

A&E, accident and emergency; EOS, eosinophils; FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; ICS, inhaled corticosteroid; IgE, Immunoglobulin E; IL, interleukin; IU, international units; LABA, long-acting ß2-agonist; ppb, parts per billion; R, receptor.

References

  1. Sanofi Genzyme. Dupixent Summary of Product Characteristics, December 2020.
  2. Asthma UK. Fighting for breath: The hidden lives of people with severe asthma 2010. Available at: http://admin.fifedirect.org.uk/weborgs/nhs/uploadfiles/publications/c64_FightingforBreathTheHiddenLivesofPeopleLivingwithSevereAsthma1.pdf. Date accessed: April 2021.
  3. Bourdin A, et al. Allergy. 2021;76(1):269–280.
  4. Sanofi Data on file. REF-98937. October 2020.
  5. Rabe KF, et al. N Engl J Med. 2018;378(26):2475–2485.
  6. Bourdin A, et al. Allergy. 2021;76(1):269–280. Supplementary Appendix S1.